2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Leukemia, Myeloid, Acute
1
Leukemia, Biphenotypic, Acute
1
Leukemia
1
Interventions
Specimen Handling
655
pembrolizumab
608
Magnetic Resonance Spectroscopy
561
Carboplatin
449
Cisplatin
398
Cyclophosphamide
396
Biopsy
380
Nivolumab
325
Paclitaxel
323
Gemcitabine
317
Radiotherapy
298
Bevacizumab
248
Dexamethasone
223
fludarabine
215
Docetaxel
202
durvalumab
195
Oxaliplatin
189
venetoclax
186
atezolizumab
183
Fluorouracil
177
Rituximab
176
Pemetrexed
173
Capecitabine
170
Radiation
168
Doxorubicin
166
Radiosurgery
161
Ipilimumab
147
Etoposide
142
Leucovorin
140
Lenalidomide
139
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Cobicistat
×
90 days
×
Clear all
NCT04065399
2026-03-18
AUGMENT-101
Syndax Pharmaceuticals
Phase 1/2
Recruiting
447 enrolled
2 FDA